Compare
Evommune, Inc. vs Tonix Pharmaceuticals Holding Corp. vs Emmaus Life Sciences, Inc. vs CV Sciences, Inc.
| Latest fiscal year | Evommune, Inc. EVMN | Tonix Pharmaceuticals Holding Corp. TNXP | Emmaus Life Sciences, Inc. EMMA | CV Sciences, Inc. CVSI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $13.00M | $13.11M | $12.45M | $13.79M |
| Revenue growth (YoY) | +85.7% | +29.8% | -25.2% | -12.2% |
| Gross margin | n/a | 49.3% (computed) | 93.1% | 49.0% |
| Operating margin | -623.6% | -959.1% | 1.9% | -3.4% |
| Net margin | -529.8% | -946.2% | -60.2% | -6.9% |
| Net income | -$68.87M | -$124.02M | -$7.49M | -$958.0K |
| EPS (Diluted) | -$11.22 | -$14.57 | -$0.12 | -$0.01 |
| Operating cash flow | -$76.44M | -$99.84M | -$11.0K | -$407.0K |
| Free cash flow | -$76.68M | -$103.21M | -$12.0K | -$516.0K |
| Cash & equivalents | $44.06M | $207.64M | $2.13M | n/a |
| Total assets | $224.95M | $277.17M | $21.44M | $6.96M |
| Total liabilities | $19.38M | $32.02M | $85.04M | $5.49M |
| Shareholders' equity | $205.57M | $245.15M | -$63.61M | $1.47M |
| Return on year-end equity | -33.5% | -50.6% | n/a | -65.3% |
| Shares outstanding | 31.52M | 12.79M | 70.19M | 184.26M |
Revenue, most recent five fiscal years
| Fiscal year | Evommune, Inc. | Tonix Pharmaceuticals Holding Corp. | Emmaus Life Sciences, Inc. | CV Sciences, Inc. |
|---|---|---|---|---|
| Latest | $13.00M Ended 2025-12-31 | $13.11M Ended 2025-12-31 | $12.45M Ended 2025-12-31 | $13.79M Ended 2025-12-31 |
| 1 year earlier | $7.00M Ended 2024-12-31 | $10.09M Ended 2024-12-31 | $16.65M Ended 2024-12-31 | $15.71M Ended 2024-12-31 |
| 2 years earlier | n/a | $7.77M Ended 2023-12-31 | $29.60M Ended 2023-12-31 | $16.00M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $18.39M Ended 2022-12-31 | $16.20M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $20.61M Ended 2021-12-31 | $20.05M Ended 2021-12-31 |